about
Bioanalytical procedures for determination of drugs of abuse in bloodToxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy')Prion infected meat-and-bone meal is still infectious after biodiesel productionToxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives.Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization.Negative ion chemical ionization gas chromatography-mass spectrometry and atmospheric pressure chemical ionization liquid chromatography-mass spectrometry of low-dosed and/or polar drugs in plasma.Transcriptional activation of heme oxygenase-1 and its functional significance in acetaminophen-induced hepatitis and hepatocellular injury in the rat.Validated assay for quantification of oxcarbazepine and its active dihydro metabolite 10-hydroxycarbazepine in plasma by atmospheric pressure chemical ionization liquid chromatography/mass spectrometry.Identification of cytochrome p450 enzymes involved in the metabolism of 4'-methyl-alpha-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes.Prevalence of new psychoactive substances: A retrospective study in hair.Drugs of abuse monitoring in blood for control of driving under the influence of drugs.Segmental hair analysis for differentiation of tilidine intake from external contamination using LC-ESI-MS/MS and MALDI-MS/MS imaging.Single hair analysis of small molecules using MALDI-triple quadrupole MS imaging and LC-MS/MS: investigations on opportunities and pitfalls.Liquid chromatography, in combination with a quadrupole time-of-flight instrument (LC QTOF), with sequential window acquisition of all theoretical fragment-ion spectra (SWATH) acquisition: systematic studies on its use for screenings in clinical andDevelopment of a high-speed MALDI-triple quadrupole mass spectrometric method for the determination of 3,4-methylenedioxymethamphetamine (MDMA) in oral fluid.Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.Long-term monitoring of opioid, sedative and anti-inflammatory drugs in horse hair using a selective and sensitive LC-MS/MS procedureFrom the Cover: Zebrafish Larvae Are Insensitive to Stimulation by Cocaine: Importance of Exposure Route and Toxicokinetics.Toxicological detection of ibuprofen and its metabolites in urine using gas chromatography-mass spectrometry (GC-MS).Trends in drug testing in oral fluid and hair as alternative matrices.New evidence for old lore--urinary bladder distension on post-mortem computed tomography is related to intoxication.Assessment of simpler calibration models in the development and validation of a fast postmortem multi-analyte LC-QTOF quantitation method in whole blood with simultaneous screening capabilities using SWATH acquisition.Postmortem distribution and redistribution of MDAI and 2-MAPB in blood and alternative matrices.A new metabolomics-based strategy for identification of endogenous markers of urine adulteration attempts exemplified for potassium nitrite.First Time View on Human Metabolome Changes after a Single Intake of 3,4-Methylenedioxymethamphetamine in Healthy Placebo-Controlled Subjects.Acute death associated with Citrobacter freundii infection in an African elephant (Loxodonta africana).Time-dependent postmortem redistribution of morphine and its metabolites in blood and alternative matrices-application of CT-guided biopsy sampling.MALDI-MS drug analysis in biological samples: opportunities and challenges.Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.Neurochemical profile of the human cervical spinal cord determined by MRS.Development and validation of an ultra-fast and sensitive microflow liquid chromatography-tandem mass spectrometry (MFLC-MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study iInhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine.Development of CT-guided biopsy sampling for time-dependent postmortem redistribution investigations in blood and alternative matrices--proof of concept and application on two cases.Influence of Different Sewer Biofilms on Transformation Rates of Drugs.Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine and its Phase I and II Metabolites following Controlled Administration to Humans.Liquid chromatography, in combination with a quadrupole time-of-flight instrument, with sequential window acquisition of all theoretical fragment-ion spectra acquisition: validated quantification of 39 antidepressants in whole blood as part of a simTitanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasome.Comparison of conventional liquid chromatography-tandem mass spectrometry versus microflow liquid chromatography-tandem mass spectrometry within the framework of full method validation for simultaneous quantification of 40 antidepressants and neurolErratum to: Long-term monitoring of opioid, sedative and anti-inflammatory drugs in horse hair using a selective and sensitive LC-MS/MS procedureThe antispasmodic drug mebeverine leads to positive amphetamine results by fluorescence polarization immunoassay (FPIA)--studies on the toxicological analysis of urine by FPIA and GC-MS.
P50
Q28299907-722B4F83-F4D1-4D4C-9D08-83C2FF20BDCCQ28373367-8A296156-083C-4520-9447-6FC05D03AD29Q28473371-910FB66B-FC76-4E6A-8D06-6A123CCCC5E7Q30679989-435AFBFE-8531-4BA9-8F07-56B08C9CD51FQ30724754-622E3EB1-63EF-43FB-BB20-B3F46921C1DFQ31035975-73438952-81DD-4368-A168-15E9868AF6A6Q31444703-69E56730-EBDA-43C1-9453-A4A8ECEC5056Q33425476-CC37A4D6-229B-46D9-8C93-368B213ECECBQ34214861-9046358E-1653-40BA-B0A6-A54BE56A7319Q34270004-3BCABA22-DDC3-476D-A7C3-EF813F4BA4F2Q34565982-71758D01-2978-4AA7-8F5D-1989B86CE987Q35189258-CBEA4EDE-726B-4421-A56B-DEADB235649BQ35308376-C47C5210-7CCC-4E48-8C30-5B5C8C8C04FBQ35347771-8808ACB8-9C8F-4E7C-8F3A-E5B31E0B92BEQ35635675-269758A2-2655-4E1E-9A8C-C1AFE27CF4D5Q35953819-3409B198-6B6C-4F00-B17B-DBB281E6AAC0Q36036984-DE74B6B9-BD1A-424B-927D-7D11142BCDD2Q36103450-BCCBF0CD-C9FC-414D-88AE-1E3D1375482EQ36748870-EB2C0EC8-F7FC-4403-BF8B-2864BEF6C196Q38266511-222BECDA-58F5-44E1-B0C8-710097DF118FQ38424469-6BEBF129-5C3F-4195-864C-2E21F78E7117Q38602710-E3D103B1-AC72-4994-8E6C-584F3CE146EFQ38603634-E05B1A1A-CBFF-402F-9C0E-9A279D0C1F81Q38621081-24E8CFBD-9539-4DAE-95CC-F168BF223E66Q38672522-B9369F2D-2978-4F30-ADA3-85535391C83BQ38695383-CB41F7E0-66AD-4FE3-AFEA-D89F3E222117Q38787500-44F6E297-3C3B-404C-9556-6415D90D02E1Q38831413-DF337077-5C76-4520-A3A8-E3D911DC65DFQ38961114-92CF1BA4-2D45-499E-B986-1EFBF2A23959Q39435670-168CE759-41D7-4E6A-B05E-A90A1A2CB94AQ39597242-8C614D97-209F-4248-960F-CC4AF5B1F21FQ40154026-1417BC18-0644-4C5B-AE82-55C9AB99A08AQ40202233-0D9034D0-9193-4E28-BCEA-CF62CAC0EE38Q40417931-55721D54-3FC5-4401-A607-80FCA713D03AQ40512842-563260B0-7E65-42C4-923B-D57B83416FB3Q40678794-07611C55-8D97-4B1E-85C9-438C9B285B4FQ41146941-A447F655-B6C3-4C3F-B286-C0DC0618AF72Q41570261-5C7483DB-5785-49EC-835C-12AAA27635F6Q42575461-3E03861B-E5A3-4B08-A6B1-E02B39E9C5F1Q43703769-106EFDE0-D46A-440E-9770-6D7EBC4D0884
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Thomas Kraemer
@ast
Thomas Kraemer
@en
Thomas Kraemer
@es
Thomas Kraemer
@nl
Thomas Kraemer
@sl
type
label
Thomas Kraemer
@ast
Thomas Kraemer
@en
Thomas Kraemer
@es
Thomas Kraemer
@nl
Thomas Kraemer
@sl
prefLabel
Thomas Kraemer
@ast
Thomas Kraemer
@en
Thomas Kraemer
@es
Thomas Kraemer
@nl
Thomas Kraemer
@sl
P106
P21
P31
P496
0000-0002-3283-606X